Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProvMAB Trial: AZD7442 (tixagevimab + cilgavimab) for COVID-19 prevention in cancer patients
TCTR20220901002Phase 3Unknown
- Sponsor
- Chulabhorn Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Chulabhorn Hospital. Status: unknown.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220901002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220901002.